Results 241 to 250 of about 288,435 (354)

Perioperative Pembrolizumab in Locally Advanced Melanoma: A Real-world Single-centre Retrospective Study.

Acta Derm Venereol
Goller S, Dege T, Schummer P, Haug L, Meir M, Gehrke T, Klein D, Goebeler M, Kneitz H, Schilling B, Gesierich A, Glutsch V.   +11 more
europepmc   +1 more source

Late-Onset Immune-Related Adverse Events in Patients with Advanced Melanoma: The LATENT Study. [PDF]

Cancers (Basel)
Pozas J, Cheruvu S, Jaganathan PP, Ganesan P, Modi A, Larkin J, Cossar L, Olsson-Brown A, Johnson A, Garbutt N, Lee R, Jones J, Macklin-Doherty A, Young K, Latent Study Investigators.   +14 more
europepmc   +1 more source

Hyperthermia and radiation in advanced malignant melanoma

, 1993
K. Engin, Leslie Tupchong, D Phil, Frank M. Waterman, David T. Moylan, Rudolph E. Nerlinger, Dennis B. Leeper   +6 more
openalex   +1 more source

MR‐DELTAnet: A Longitudinal MRI‐Transformer Model Predicting Pathological Complete Response and Revealing Immune Microenvironment via scRNA‐seq in Locally Advanced Rectal Cancer

Advanced Science, EarlyView.
The MR‐DELTAnet model utilizes longitudinal MRI to predict treatment response after neoadjuvant chemoradiotherapy in locally rectal cancer patients, accurately identifying patients likely to achieve pathological complete response for personalized management.
Wuteng Cao, Huaxian Chen, Jiao Li, Yihui Zheng, Liqing Xie, Guozhong Xiao, Zeyan Wang, Fen Yuan, Junhong Chen, Chongbao Sun, Jing Dai, Jinping Zeng, Xinhua Wang, Lei Wu, Hongcheng Lin   +14 more
wiley   +1 more source

Uncovering Cellular Interactome Drivers of Immune Checkpoint Inhibitor Response in Advanced Melanoma Patients. [PDF]

Cell Mol Bioeng
Ladd S, Talkington AM, O'Sullivan M, Barnes RW, Wessel RE, Hanson GF, Dolatshahi S.   +6 more
europepmc   +1 more source

Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma

, 2014
Brenda Hagen, Van Anh Trinh
openalex   +2 more sources

A Programmable Nanoreactor Orchestrates Cascade of DNA Sensing to Amplify cGAS‐STING Activation for Cancer Immunotherapy

Advanced Science, EarlyView.
A programmable nanoreactor was engineered for precise cGAS‐STING pathway activation in cancer immunotherapy. This strategy bridges targeted tumor DNA damage with DC immunomodulation, providing a translatable platform to unlock innate and adaptive antitumor immunity.
Shuang Liang, Yiwei Tian, Feiyu Zhao, Yue Han, Kongshuo Ma, Linna Hai, Kaiqing Yun, Yueyang Zhao, Siqi Zhang, Ziyi Zhang, Yuxuan Peng, Kuan Hu, Jing Zhong, Bai Xiang, Zhaohui Wang   +14 more
wiley   +1 more source

MelanoDB: A dataset of clinical and molecular features of patients with advanced melanoma treated with MAPK inhibitors. [PDF]

Sci Data
Dandou S, Vendrell JA, Solassol J, Louveau B, Lebbé C, Mourah S, Rambow F, Richard E, Du Manoir S, Mangé A, Coopman PJ, Radulescu O, Larive RM.   +12 more
europepmc   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Advanced Science, EarlyView.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang, Gulizeba Aimaiti, Yuanye Guan, Yuzhe Sha, Wei Zhou, Jiefeng Shen, Bo Zhao, Wei‐En Yuan   +7 more
wiley   +1 more source

Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047. [PDF]

J Immunother Cancer
Regan MM, Ascierto PA, Lipson EJ, Palaia J, Moshyk A, Selvan A, Lao CD, Atkins MB, McDermott DF, Potluri R, Ranjan S, Bilthare S, Long GV, Stephen Hodi F, Tawbi H, Schadendorf D.   +15 more
europepmc   +1 more source